(Hypertension. 2000;35:32.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
Potentiation of the Vascular Response to Kinins by Inhibition of Myocardial Kininases
From the Institute of Experimental and Clinical Pharmacology and Toxicology (A.D., S.W., U.S., P.D.), Medical University of Lübeck, Lübeck, Germany; Biochemistry Department (J.M.S.), University of Colorado Medical School, Denver, Colo; and Global Product Planning and Development (N.I.), Fujisawa Pharmaceutical Co., Yodogawa-Ku, Osaka, Japan.
Correspondence to Dr A. Dendorfer, Medical University of Lübeck, Institute of Experimental and Clinical Pharmacology and Toxicology, Ratzeburger Allee 160, D-23538 Lübeck, Germany. E-mail dendorfe{at}medinf.mu-luebeck.de
Abstract—Inhibitors of angiotensin I–converting enzyme (ACE) are very efficacious in the potentiation of the actions of bradykinin (BK) and are able to provoke a B2 receptor–mediated vasodilation even after desensitization of this receptor. Because this activity cannot be easily explained only by an inhibition of kinin degradation, direct interactions of ACE inhibitors with the B2 receptor or its signal transduction have been hypothesized. To clarify the significance of degradation-independent potentiation, we studied the vasodilatory effects of BK and 2 degradation-resistant B2 receptor agonists in the isolated rat heart, a model in which ACE and aminopeptidase P (APP) contribute equally to the degradation of BK. Coronary vasodilation to BK and to a peptidic (B6014) and a nonpeptidic (FR190997) degradation-resistant B2 agonist was assessed in the presence or absence of the ACE inhibitor ramiprilat, the APP inhibitor mercaptoethanol, or both. Ramiprilat or mercaptoethanol induced leftward shifts in the BK dose-response curve (EC50=3.4 nmol/L) by a factor of 4.6 or 4.9, respectively. Combined inhibition of ACE and APP reduced the EC50 of BK to 0.18 nmol/L (ie, by a factor of 19) but potentiated the activity of B6014 (EC50=1.9 nmol/L) only weakly without altering that of FR190997 (EC50=0.34 nmol/L). Desensitization of B2 receptors was induced by the administration of BK (0.2 µmol/L) or FR190997 (0.1 µmol/L) for 30 minutes; the vascular reactivity to ramiprilat or increasing doses of BK was tested thereafter. After desensitization with BK, but not FR190997, an additional application of ramiprilat provoked a B2 receptor–mediated vasodilation. High BK concentrations were still effective at the desensitized receptor. The process of desensitization was not altered by ramiprilat. These results show that in this model, all potentiating actions of ACE inhibitors on kinin-induced vasodilation are exclusively related to the reduction in BK breakdown and are equivalently provoked by APP inhibition. The desensitization of B2 receptors is overcome by increasing BK concentrations, either directly or through the inhibition of ACE. These observations do not suggest any direct interactions of ACE inhibitors with the B2 receptor or its signal transduction but point to a very high activity of BK degradation in the vicinity of the B2 receptor in combination with a stimulation-dependent reduction in receptor affinity.
Key Words: bradykinin • angiotensin-converting enzyme • receptor, bradykinin • rats • heart
This article has been cited by other articles:
 |
|
 |
|
  D. O. Sivieri Jr, L. B. Bispo-da-Silva, E. B. Oliveira, A. C. Resende, and M. C. O. Salgado Potentiation of Bradykinin Effect by Angiotensin-Converting Enzyme Inhibition Does Not Correlate With Angiotensin-Converting Enzyme Activity in the Rat Mesenteric Arteries Hypertension, July 1, 2007; 50(1): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Fleming Signaling by the Angiotensin-Converting Enzyme Circ. Res., April 14, 2006; 98(7): 887 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Sulpizio, M. A. Pullen, R. M. Edwards, J. B. Louttit, R. West, and D. P. Brooks Mechanism of Vasopeptidase Inhibitor-Induced Plasma Extravasation: Comparison of Omapatrilat and the Novel Neutral Endopeptidase 24.11/Angiotensin-Converting Enzyme Inhibitor GW796406 J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1306 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. U. Norman, S. B. Reeve, V. Dive, A. I. Smith, and R. A. Lew Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems: Endopeptidases 3.4.24.15 and 24.16 in endothelial cells: potential role in vasoactive peptide metabolism Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H1978 - H1984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Multani, R. S. Krombach, A. T. Goldberg, M. K. King, J. W. Hendrick, J. A. Sample, S. C. Baicu, C. Joffs, M. deGasparo, and F. G. Spinale Myocardial Bradykinin Following Acute Angiotensin-Converting Enzyme Inhibition, AT1 Receptor Blockade, or Combined Inhibition in Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 369 - 376. [Abstract] [PDF]
|
|
|
|
|
|
A. Dendorfer, S. Rei{beta}mann, S. Wolfrum, W. Raasch, and P. Dominiak Potentiation of Kinin Analogues by Ramiprilat Is Exclusively Related to Their Degradation Hypertension, July 1, 2001; 38(1): 142 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dendorfer, S. Wolfrum, M. Wagemann, F. Qadri, and P. Dominiak Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats Am J Physiol Heart Circ Physiol, May 1, 2001; 280(5): H2182 - H2188. [Abstract] [Full Text] [PDF]
|
|